What's behind Hims & Hers Health's latest stock pullback?
Hims & Hers Health Inc (HIMS) dropped 3.99% after broad selling momentum continued to pressure the stock, even as the company introduced its new Peptides+ product line amid an expansion in compounded peptide and longevity treatments. The move is reinforced by HIMS trading below its 20-day, 50-day, and 200-day moving averages, highlighting persistent bearish momentum and a prevailing downward trend.
Highlights
- Hims & Hers Health introduced Peptides+, adding five new peptide and longevity treatments compounded in U.S. pharmacies after regulatory changes.
- Revenue increased 49% year over year to $890.4 million and subscribers rose 13% to 2.8 million, but the company posted an operating loss after a prior-year profit.
- Shares of Hims & Hers Health last traded at $16.38 under broad selling pressure, with technical indicators confirming downside momentum and an expected five-day range of $14.82 to $17.94.
Peptides+ rollout and subscriber growth met by renewed losses, insider sale
Hims & Hers Health launched Peptides+, a new offering introducing five U.S.-compounded peptide and longevity treatments, following recent regulatory changes that eased restrictions on such compounds. Products are prepared in licensed pharmacies under state guidelines, with further expansion planned to include additional peptides. The company reported a 49% year-over-year revenue increase to $890.4 million and a 13% rise in subscribers to 2.8 million, but returned to operating losses after a prior-year profit. The CFO also sold 3,518 shares on November 17, 2026, though price action has remained under broader selling pressure.
Bearish technical trend confirmed as multiple oversold signals emerge
Hims & Hers Health is trading below the 20-day, 50-day, and 200-day moving averages at $24.13, $27.01, and $26.55, respectively, which signals broad pressure from sellers and a loss of short-, medium-, and long-term momentum. Immediate resistance is at $17.02 and support at $14.82, with additional overhead levels enforcing the dominant bearish trend. Momentum remains negative, confirmed by the MACD and ADX, while intraday volatility stands at 6.93%. RSI, Stochastic RSI, and CCI are all in oversold zones, suggesting potential selling exhaustion but not a confirmed bottom. BBP and the Awesome Oscillator also align with continued seller dominance, as intraday action brought the price near session lows after an early upside gap faded.
Earlier, analysts noted that Hims & Hers Health was experiencing sustained bearish momentum despite ongoing product portfolio expansion. The latest price action confirms continued technical weakness, with further downside risk if key support at $14.82 fails to hold in the days ahead.